Recruiting Macular Degeneration Studies in Campbell
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by ...
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is character...
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-...
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-w...
About Macular Degeneration Clinical Trials in Campbell
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in Americans over 50, affecting over 11 million people. Wet (neovascular) AMD involves abnormal blood vessel growth under the retina, while dry AMD involves gradual thinning of the macula and accumulation of drusen deposits. Current treatment for wet AMD relies on anti-VEGF injections (ranibizumab, aflibercept, faricimab), with newer high-dose and extended-interval formulations reducing treatment burden. For geographic atrophy (advanced dry AMD), complement inhibitors like pegcetacoplan (Syfovre) represent the first approved treatments. Clinical trials are testing gene therapies, implantable drug delivery systems, stem cell therapies, and novel targets beyond VEGF for both wet and dry AMD.
There are currently 4 macular degeneration clinical trials recruiting participants in Campbell, CALIFORNIA. These studies are seeking a combined 1,848 participants. Research is being sponsored by AbbVie, Adverum Biotechnologies, Inc., Hoffmann-La Roche. Clinical trial participation is free and participants receive study-related medical care at no cost.
Macular Degeneration Clinical Trials in Campbell — FAQ
Are there macular degeneration clinical trials in Campbell?
Yes, there are 4 macular degeneration clinical trials currently recruiting in Campbell, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Campbell?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Campbell research site will contact you about next steps.
Are clinical trials in Campbell free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Campbell studies also compensate for your time and travel.
What macular degeneration treatments are being tested?
The 4 active trials in Campbell are testing new therapies including novel drugs, biologics, and treatment approaches for macular degeneration.
Data updated March 2, 2026 from ClinicalTrials.gov